Caligenix

Novigenix analyses large amounts of RNA data from different patients’ blood to generate precise information about the patient response to cancer, the evolution of the cancer, and response to treatment. Novigenix solutions employ cutting edge molecular technologies ranging from NGS to RT-PCR based platforms, and they leverage the company’s proprietary Immuno-Transcriptomics LITOSeek™ platform which has been optimized and standardized for integrating patient multi-omics data with advanced Machine Learning and artificial intelligence approaches to map the response of the immune system to onset and progression of disease. We are a pioneering company made up of experienced, bold and dedicated individuals with a clear understanding of complex host immune response pathways and data-driven intelligent algorithms. We provide new and actionable information on patient immune response to disease using expertise in immunology, molecular biology, bioinformatics, and machine learning to reveal, each day, more insights into the heterogeneity of host immune response for development of novel therapeutic modalities that can improve patient’s therapeutic journeys. We develop precise information about the risk and the stage of cancer, and likely response to immunotherapy. Over the past decade the Novigenix team has developed core competencies in development and measurement of RNA molecular biomarkers that are indicators of the presence or severity of a disease, in development of state-of-the-art data analytical models, and in regulatory approval of IVD products. We cooperate closely with biopharmaceutical companies and academic centers of excellence to leverage Immuno-Transcriptomics and improve our understanding of disease progression and response to therapy, integrating patient data and the host’s immune response to provide a holistic view of the tumor-host interaction. There is a gap in precise information to guide therapy development and clinical decision making.

Based in Irvine, California with R&D lab facilities located in San Diego, California, Cellgen’s core platform is based on a portfolio of patent-pending technologies exclusively licensed from the laboratory of Dr. Yuhwa Lo at the University of California San Diego. The Cellgen team consists of experienced diagnostic, clinical and entrepreneurial executives that have unique insights into the development of a successful start-up enterprise through initial product launch. Cellgen also retains a strategic and medical advisory team composed of industry veterans and opinion leaders with strong track records in the diagnostic and medical industries. Collectively, we have over 100 years of diagnostic experience along with over 150 products commercialized through the FDA.

Heligenics is a biotechnology company focused on functional genomics research and services. Heligenics provides custom services in the drug development and molecular diagnostic space. What sets Heligenics apart is our innovative approaches and proprietary technologies, making them a valuable partner in genomics research. We are the first company in the pharmaceutical space to enable high-content screening for biologics, a previously well-established method for small molecule therapies. Heligenics believes that people can live healthier lives. At Heligenics we produce all genetic variants and test their functional impact en masse in live human cells by delivering Improved Diagnostics, Faster and Better Companion Diagnostics, Truly Precision Clinical Trials, and Novel Biologics and Biobetters. Martin Schiller of the University of Nevada, Heligenics Inc. We offer comprehensive genomic solutions to pharmaceutical and biotechnology companies, as well as healthcare providers, to advance personalized medicine and precision therapeutics.

NVIGEN is a nanotechnology empowered personalized medicine innovator. NVIGEN technology empowers revolutionary personalized medicine with highly accurate and NGS data efficient assays providing integrative DNA, RNA, Protein, and Cell information. We are focusing on the development of a comprehensive circulating bio-marker biopsy technology, NVIGEN X™, to predict cancer recurrence at the earliest possible time and guide the most effective personalized therapy. NVIGEN X™ is enabled by the state-of-the-art molecularly engineered nanoparticles, MagVigen™ and MyQuVigen™, to efficiently capture and identify molecular information from proteins, cells and nucleic acids. We are developing NVIGEN X™ into accurate, automated and FDA approved clinical instruments and reagent kits deployable at hundreds and thousands of hospitals, turning fatal cancers into manageable diseases. We are happy to share the versatility of nanoscience and our 2-decade innovation with the community to develop solutions to empower the advancement of biomedical research and applications in sequencing, biopsy, genomics, diagnostics, gene/cell therapy, and drug delivery etc., with the same goal of providing better cares to patients and enabling healthier lives of every human being. Both the NVIGEN X® test and the NERNST™-Seq are now open for clinical research use. NVIGEN works closely with our collaborators to develop new technology, products and applications.

At Celligenics, we are reinventing the way forward by harnessing regenerative technology to support the body in repairing, regenerating, and restoring itself to a state of well-being. Established in 2016, Celligenics is a spin-off of the Agency for Science, Technology & Research (A*STAR), Singapore’s leading public R&D agency, and one of A*STAR’s top 10 new biotech start-ups in 2018. We are also a finalist for Singapore’s Emerging Enterprise Award 2021, the top business award jointly organised by OCBC Bank and The Business times that recognises the ambitions of emerging enterprises. Celligenics Announces China Market Entry, & Signs MOU With West China Hospital. Celligenics, NTU, & SRIS Collaborate On New Therapy For Chronic Wounds (Sep 2021). Our regenerative extract is a platform technology, with limitless application potential. Two product lines are currently under development, with more to come. Traditional skincare products lose their effectiveness over time, and stronger and more expensive products are then required to maintain the health of our skin.

Genix.ai is a machine learning assisted clinical investigation service using next generation sequencing(NGS) and biomedical imaging data. We are providing personalized treatment strategies for clinicians with timely detection of biomarkers to fight rare diseases in infants, extend and improve quality of life with cancer patients and cost effective detection of complex infections. Genix.ai as a platform aims to bridge the gap between traditional diagnostic methods and effective personalized medicine. Our services include three major categories namely sequencing, analysis and data solutions for clinical research. AI technology is perfect for best business solutions & we offer help to achieve your goals. Tell us about your product and we will give you expert assistance. Having a home based business is a wonderful asset to your life. More sequencing data in size than any other service provider in the industry.